Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Lights and shadows of cyclophosphamide in the treatment of multiple sclerosis.
[Evaluation and quantification of spasticity: a review of the clinical, biomechanical and neurophysiological methods].
Long-term Safety, Tolerability and Efficacy of BAF312 Given Orally in Patients With Relapsing-remitting Multiple Sclerosis
Immune status following alemtuzumab treatment in human CD52 transgenic mice.
Integrated analysis of daclizumab HYP pharmacokinetics from three phase 1 studies
Human endogenous retroviruses and multiple sclerosis: innocent bystanders or disease determinants?
The Canadian cooperative trial of cyclophosphamide and plasma exchange in progressive multiple sclerosis. The Canadian Cooperative Multiple Sclerosis Study Group.
Colestipol May Quickly Eliminate Teriflunomide
Treatment of Relapsing-Remitting Multiple Sclerosis After 24 Doses of Natalizumab: Evidence From an Italian Spontaneous, Prospective, and Observational Study (the TY-STOP Study).
Sanofi MS drug nears green light after pass-the-parcel marathon
GlaxoSmithKline and Genmab refocus development programme for ofatumumab in autoimmune indications
Laquinimod Phase IIa Study in Active Crohn's Disease
Oral Laquinimod for Multiple Sclerosis Granted Fast Track Status by FDA
Effects of Inhibitors of the Renin-Angiotensin System on the Efficacy of Interferon beta-1b: A post hoc Analysis of the BEYOND Study.
Pharmacokinetic properties and metabolism of idebenone.
Evidence for the efficacy of interferon beta-1b in delaying the onset of clinically definite multiple sclerosis in individuals with clinically isolated syndrome.
Estimating Time to Disease Progression Comparing Transition Models and Survival Methods-An Analysis of Multiple Sclerosis Data.
Reactive astrocytes as therapeutic targets for CNS disorders.
Tecfidera(®): an approach for repurposing.
Volumetric comparisons of supratentorial white matter hyperintensities on FLAIR MRI in patients with migraine and multiple sclerosis.
Treatment of acute transverse myelitis and its early complications.
High dose cyclophosphamide preferentially targets naïve T (CD45/CD4/RA+) cells in CIDP and MS patients.
Immunology 2013
BRAVO Study: Laquinimod Double Blind Placebo Controlled Study in RRMS Patients With a Rater Blinded Reference Arm of Interferon β-1a (Avonex®)
Intensive immunosuppression in progressive multiple sclerosis. A randomized, three-arm study of high-dose intravenous cyclophosphamide, plasma exchange, and ACTH.

Pages